• LAST PRICE
    12.6000
  • TODAY'S CHANGE (%)
    Trending Up0.3800 (3.1097%)
  • Bid / Lots
    12.5600/ 6
  • Ask / Lots
    12.6500/ 6
  • Open / Previous Close
    12.2700 / 12.2200
  • Day Range
    Low 12.1000
    High 12.7200
  • 52 Week Range
    Low 7.6400
    High 30.1886
  • Volume
    268,962
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 12.22
TimeVolumeCGEM
09:32 ET494512.14
09:33 ET438912.33
09:35 ET250012.205
09:37 ET73212.3
09:39 ET89012.34
09:42 ET1511912.35
09:46 ET20012.385
09:48 ET130012.34
09:50 ET172012.42
09:51 ET40012.34
09:53 ET300012.44
09:55 ET291412.36
09:57 ET60012.26
10:04 ET152312.195
10:06 ET60012.24
10:08 ET92712.32
10:09 ET121412.365
10:11 ET166112.3
10:13 ET10012.29
10:15 ET10012.29
10:18 ET10012.285
10:20 ET30012.29
10:22 ET10012.29
10:24 ET31612.345
10:26 ET133612.345
10:27 ET454212.3
10:29 ET270012.35
10:31 ET110012.325
10:33 ET214912.305
10:36 ET30012.31
10:38 ET20012.325
10:40 ET360812.34
10:42 ET10012.37
10:44 ET911312.385
10:45 ET553212.29
10:51 ET150012.27
10:54 ET40012.295
10:56 ET359312.24
10:58 ET436812.21
11:00 ET296812.19
11:02 ET476212.18
11:03 ET115412.17
11:05 ET240812.15
11:07 ET218712.25
11:09 ET80012.34
11:12 ET20012.325
11:14 ET150012.265
11:20 ET50012.32
11:21 ET30012.35
11:23 ET180012.36
11:25 ET100012.35
11:27 ET136212.35
11:30 ET1799012.39
11:32 ET263512.54
11:34 ET224512.5
11:36 ET10012.49
11:38 ET200012.59
11:39 ET30012.62
11:41 ET20012.62
11:43 ET30012.68
11:45 ET100012.605
11:48 ET90012.605
11:50 ET10012.67
11:52 ET150012.68
11:54 ET20012.66
11:56 ET1243312.64
11:59 ET10012.7
12:03 ET30912.7
12:06 ET50012.7
12:08 ET536112.6
12:10 ET232912.61
12:14 ET60012.64
12:19 ET87112.685
12:21 ET131112.68
12:24 ET10012.69
12:26 ET38612.69
12:30 ET110012.68
12:32 ET110012.66
12:33 ET20012.64
12:35 ET25012.63
12:42 ET71912.64
12:44 ET30012.68
12:46 ET30012.67
12:48 ET453612.6
12:50 ET290012.5884
12:51 ET70012.55
12:53 ET24812.53
12:55 ET10012.53
12:57 ET10012.49
01:00 ET10012.5
01:02 ET80012.47
01:04 ET54012.51
01:09 ET20012.57
01:11 ET85212.61
01:13 ET10012.62
01:15 ET40012.64
01:20 ET10012.62
01:22 ET42212.64
01:24 ET30012.615
01:26 ET190612.605
01:29 ET76812.605
01:33 ET100012.64
01:36 ET80012.67
01:38 ET70012.68
01:40 ET344712.61
01:44 ET70012.58
01:45 ET58712.5739
01:47 ET20012.63
01:49 ET10012.625
01:51 ET102912.625
01:54 ET88112.59
01:58 ET82112.6
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCGEM
Cullinan Therapeutics Inc
711.5M
-4.4x
---
United StatesORKA
Oruka Therapeutics Inc
717.5M
-3.4x
---
United StatesCRGX
CARGO Therapeutics Inc
722.1M
-4.8x
---
United StatesOCS
Oculis Holding AG
615.7M
-7.3x
---
United StatesERAS
Erasca Inc
734.5M
-3.3x
---
United StatesREPL
Replimune Group Inc
755.0M
-5.2x
---
As of 2024-11-22

Company Information

Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Contact Information

Headquarters
One Main Street, Suite 1350CAMBRIDGE, MA, United States 02142
Phone
617-410-4650
Fax
302-655-5049

Executives

Independent Chairman of the Board
Anthony Rosenberg
President, Chief Executive Officer, Director
Nadim Ahmed
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Mary Fenton
Chief Scientific Officer
Jennifer Michaelson
Chief Legal and Compliance Officer, Company Secretary
Jacquelyn Sumer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$711.5M
Revenue (TTM)
$0.00
Shares Outstanding
58.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.17
EPS
$-2.88
Book Value
$10.58
P/E Ratio
-4.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.